Tevogen Bio to Host Panel Discussions "AI In Biopharma: Next Frontier of Medical Innovation" and "Pioneering the Economics of Health: Balancing Access and Outcomes" During J.P. Morgan Healthcare Conference

Company Overview - Tevogen Bio is a clinical-stage specialty immunotherapy company focused on developing precision T cell therapies for infectious diseases, cancers, and neurological disorders [1] - The company aims to address significant unmet needs in large patient populations through advanced science and innovative business models [1] - Tevogen has reported positive safety data from its proof-of-concept clinical trial and owns key intellectual property assets, including three granted patents and multiple pending patents related to artificial intelligence [1] Leadership and Team - Tevogen is led by a team of experienced industry leaders and distinguished scientists with expertise in drug development and global product launches [2] - The leadership emphasizes the importance of accessible personalized therapeutics as the next frontier of medicine [3] Upcoming Events - Tevogen will host panel discussions at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California, on January 13, 2025 [6][7] - The conference is recognized as the largest healthcare investment symposium, connecting industry leaders, fast-growth companies, and the investment community [7] - Topics to be discussed include the economics of health and the role of AI in biopharma, highlighting how AI can revolutionize drug discovery and enhance patient accessibility [7][8]